InPractice Survey on the Treatment of Hypercholesterolemia

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00523796
First received: August 30, 2007
Last updated: February 15, 2011
Last verified: February 2011
  Purpose

This is a multi-centre survey of patients who are currently on lipid-lowering pharmacological treatment. Data collection for each patient will take place at one visit.


Condition
Hypercholesterolemia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: InPractice Survey on the Treatment of Hypercholesterolemia

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Estimated Enrollment: 2500
Study Start Date: February 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care

Criteria

Inclusion Criteria:

  • Subject must be 18 years of age or older of either sex.
  • Subject is on lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00523796

Locations
Vietnam
Research Site
Hanoi, Vietnam
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Pham Gia Khai, Prof Vietnamese Cardiovascular Association
Study Chair: Nguyen Manh Phan, Prof Vietnamese Cardiovascular Association
Study Director: Than Trong Son, MD AstraZeneca
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00523796     History of Changes
Other Study ID Numbers: NIS-CVN-CRE-2007/1, VN-NIS-0001
Study First Received: August 30, 2007
Last Updated: February 15, 2011
Health Authority: Vietnam: Ho Chi Minh City Health Service

Keywords provided by AstraZeneca:
dyslipidemia
in practice survey
Vietnam

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on August 28, 2014